30 closest matches · ranked by relevance
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Brain Cancer · Gliomas
Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…
Malignant Central Nervous System Neoplasm · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Number of Participants With Grade 2 or Higher Toxicities — 0; 0 Participants
Malignant Glioma
Primary: Central Nervous System (CNS) Toxicity — 1 participants
Pediatric Central Nervous System Tumor
Primary: Sensitivity and Specificity of Tozuleristide Fluorescence to Detect Tumor in Equivocal (Ambiguous) Tissue During Surgery When Imaged With the Canvas System — 79.8; 34.7…
Brain Tumor · Central Nervous System Tumor
Primary: Event-free Survival — 1; 1; 0; 0 participants
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Breast Cancer · Leptomeningeal Metastasis
Primary: Total Number of Participants With Leptomeningeal Metastasis Detected (ER Status) — 3; 1 Participants
Central Nervous System Tumors
Primary: Measurement of Number of Adverse Events — 4; 6; 3; 5 Adverse events
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Brain and Central Nervous System Tumors · Lymphoma
Primary: Number of Phase I Participants Experiencing Toxicity — 1; 3 Participants
Central Nervous System Nongerminomatous Germ Cell Tumor · Childhood Germinoma
Primary: 3-year Progression-free Survival (PFS) Rate of Patients With Nongerminomatous Germ Cell Tumor (NGGCT) Who Were Treated With Reduced Dose Whole Ventricular-field…
Recurrent Childhood Anaplastic Astrocytoma · Recurrent Childhood Brain Stem Glioma · Recurrent Childhood Ependymoma
Primary: Relative Phosphorylation of ERBB2 (Molecular Biology Objective) — .21; .50 ratio
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Meningioma
Primary: 6 Month Progression Free Survival — 11; 44 percentage of patients
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Brain Neoplasms, Primary Malignant
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 0 Participants
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Chemotherapeutic Agent Toxicity · Cognitive/Functional Effects · Lymphoma
Primary: Progression-free Survival — 2.1; NA years — p=0.015
Central Nervous System Tumor, Pediatric
Primary: 2-yr Overall Survival — 0.70 probability
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Lung Cancer
Primary: Overall Survival — 28.5; 25.3 months — p=0.2853
Brain Neoplasms, Malignant, Primary
Primary: Cmax — 11.108; 10.575 mcg/mL — p=<0.05
Brain Cancer
Primary: Number of Participants Who Received PET/CT and MRI Perfusion Studies — 53; 95 Participants
Brain Tumors
Primary: Progression Free Survival — 70 percentage of no progression
Central Nervous System Neoplasms · Medulloblastoma
Primary: Percentage of Participants With an Objective Response and Long-term Stable Disease — 0; 11.1; 10.5; 0 percentage of participants
CNS Cancer · Meningioma · Intracranial Hemangiopericytoma
Primary: Overall Objective Response — 1; 0; 1; 0 participants
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05